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ABSTRACT  
Objective: A number of large randomized clinical trials demonstrated that lipid lowering successfully reduced cardiovascular events and death in 
patients with diabetes. Recent studies have reported that multiple transcription factors are involved in regulation of lipid metabolism in diabetic 
subjects. Numerous plant extracts and formulations have been shown to regulate the expression of transcription factors which in turn normalize 
lipid abnormalities in diabetic patients. In this series, sugnil, a traditional anti-diabetic polyherbal formulation was assessed for its regulatory effect 
on the expression of transcription factors in lipid metabolism of streptozotocin induced diabetic rats. 
Methods: The mRNA expressions of fatty acid synthesis related genes such as SREPB-1 and SREPB-2 and fatty acid decomposition related gene 
PPARα were measured by real-time RT-PCR using an appropriate primers and thermal cycler conditions. 
Results: Oral administration of sugnil to diabetic rats for 42 consecutive days effectively normalized the expression of these transcription factors to 
near normal as in control rats. Expression of PPAR-α was found to be up-regulated that leads to diminished expression of SREBP-2 in the liver of 
diabetic rats treated with sugnil. Treatment with sugnil also down regulated the SREBP-1 expression in the kidney of diabetic rats.  
Conclusion: The molecular mechanisms of action of sugnil in the regulation the lipid profile in diabetic rats might be normalizing the expression of 
these transcription factors.  
Keywords: Transcription factors, PPARα, SREPB-1, SREPB-2. 
 
INTRODUCTION  
Lipid abnormalities in diabetes mellitus results in increased risk of 
cardiovascular diseases, coronary insufficiency, myocardial 
infarction. Cardiovascular complications especially atherosclerosis 
has become a predominant cause of death in diabetic patients. Lipid 
management has been considered as an effective approach to reduce 
cardiovascular risk in diabetes subjects [1]. Thus, to reduce the risk 
of late complications and negative outcome of diabetes mellitus, not 
only the control of blood glucose levels, but also lipid levels is 
necessary. A traditional antidiabetic polyherbal formulation, 
marketed in the brand name of sugnil is selected for current 
investigation. Sugnil consists of ingredients from nine medicinal 
plants viz Aristolochia bracteata, Balsamodendron mukul, Casearia 
esculanta, Cassia auriculata, Coscinium fenestratum, Curcuma longa, 
Eugenia jambolana, Gymnema sylvestre, and 
Changes in gene expression are an important component of the 
pathogenesis of diabetes [3,4]. Multiple transcription factors are 
involved in the regulation of both carbohydrate and lipid 
metabolism either directly or through interaction with insulin and a 
large number of insulin-regulated genes have been identified in liver 
and adipose tissue [5]. Transcription factors are soluble proteins 
that are able to bind to DNA. Their binding to promoter sites of 
genes influences the transcription of genes, leading to up- or down-
regulation of gene expression. In recent years, numerous plant 
extracts and plant formulations have been shown to regulate the 
expression of transcription factors and genes in metabolic pathways 
of different diabetic animal models [6-8]. In the present study, the 
effect of sugnil on the expression of transcriptional factors such as 
peroxisome proliferator-activated receptor-α (PPAR-α), sterol 
regulatory element-binding protein-2 (SREBP 2) and sterol 
regulatory element-binding protein-1 (SREBP 1) were assessed in 
streptozotocin induced diabetic rats using RT-PCR assay. 
Peroxisome proliferator-activated receptor (PPAR) belong to a 
superfamily of nuclear, ligand-activated transcription factors, which 
play an important role in the transcriptional regulation of genes 
responsible for the control of lipid utilization and storage, and 
modulation of lipoprotein metabolism, adipocyte differentiation and 
insulin action [9]. PPARs consist of three nuclear receptor isoforms, 
PPAR alpha, PPAR delta and PPAR gamma, encoded by separate 
genes [10]. PPAR-α isoform is predominantly expressed in the liver 
and regulates the transcription of genes involved in hepatic fatty 
acid uptake and oxidation [11]. PPAR-α agonists have been used for 
over 40 years in the treatment of dyslipidemia, mainly due to their 
hypolipidemic actions, such as lowering triglyceride (TG) and raising 
high density lipoprotein levels [12]. However, these agents also 
produce hepatic peroxisome proliferation, hypertrophy and 
hyperplasia in rodents [13]. Alternatively, numerous plant extracts 
and traditional plant formulations have been reported to have 
PPAR-α modulatory activity in different diabetic animal models [14].  
Triphala. Preparation of 
Sugnil is based on traditional methods in accordance with the 
procedure suggested in the antique literature (Table 1). Our 
previous study has reported the antihyperlipidemic potency of 
sugnil in streptozotocin induced diabetic rats [2]. In this study, an 
attempt has been made to investigate the molecular mechanism of 
sugnil action in lowering lipid levels in experimental animals. 
Sterol regulatory element-binding proteins (SREBPs) are 
transcription factors that regulate fatty acid and cholesterol 
synthesis. SREBPs belong to basic helix-loop-helix-leucine zipper 
family and activate the entire program of fatty acid and cholesterol 
synthesis in liver [15,16]. Three isoforms of SREBP are known in 
mammals, SREBP- 1a, SREBP-1c and SREBP-2. In most animal 
tissues, SREBP-1c is the predominant SREBP-1 isoform [17]. 
Multiple lines of evidence suggest that SREBP-1 and SREBP-2 have 
different relative effects on target genes. SREBP-1 preferentially 
activates genes involved in fatty acid synthesis, including acetyl CoA 
carboxylase and fatty acid synthase (FAS), whereas SREBP-2 
preferentially activates genes involved in cholesterol biosynthesis 
such as hydroxymethylglutaryl CoA synthase, hydroxyl 
methylglutaryl CoA reductase, farnesyl diphosphate synthase, and 
squalene synthase [18]. 
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Table 1: Description of sugnil constituents 
S. No.  Botanical name  Common name  Part used  Concentration 
(mg/100mg) 
1. Aristolochia bracteata  Birth wort  Whole plant 10 
2. Balsamodendron mukul  Indian bdellium tree Gum 10 
3. Cassia auriculata  Tenners cassia Flower 12.5 
4 Casearia esculanta  Kadala-zhinjill  Stem  10 
5. Coscinium fenestratum  Tree turmeric Bark 12.5 
6. Curcuma longa  Turmeric Tubers 10 
7. Eugenia jambolana  Jamun  Seeds 12.5 
8. Gymnema sylvestre  Gurmar  Leaves 12.5 
9. Triphala  Indian goose berry   
 Emblica officinalis  
Terminalia bellirica  
Terminalia chebula  
Emblic myrobalan  
Belleric myrobalan  
Chebulic myrobalan  
Fruits 10 
 
MATERIALS AND METHODS 
Animals 
Male albino Wistar rats of body weight ranging from 150-180 g were 
procured from the Central Animal House, Rajah Muthiah Medical 
College, Annamalai Nagar. Six rats were allocated per polypropylene 
cage at a temperature of 22-24°C and humidity 30 - 35 % in a 
controlled room. The rats were maintained under 12h,12h light,dark 
cycle. Food [Amrut Laboratory Animal Feed, Pranav Agro Industries 
Ltd., Bangalore, India] and water were available ad libitum to 
animals. The experiments were designed and conducted according 
to the ethical norms approved by the Institutional Animal Ethics 
Committee [IAEC] of Annamalai University. 
[No.160/1999/CPCSEA/552]. The animals were maintained in 
accordance with the Indian National Law on Animal Care and use. 
Chemicals 
Streptozotocin and primers for RT-PCR analysis were purchased 
from Sigma-Aldrich Pvt. Ltd., MO, USA. TriZol reagent and cDNA 
conversion kits were purchased from Invitrogen, Life Technologies, 
USA. Biochemicals, chemicals and solvents of analytical grade were 
purchased from Himedia Laboratories Pvt. Ltd., Mumbai, India or 
from Sisco Research Laboratories Pvt Ltd., Mumbai, India.  
Induction of experimental diabetes  
Rats were fasted for 16 h prior to induction of diabetes. Rats 
received single intraperitoneal injection of 55mg/kg body weight 
STZ (Sigma, St Louis, MO, USA) freshly dissolved in 0.1 mol/L cold 
sodium citrate buffer, pH 4.5 [19]. Control rats received equivalent 
amount of buffer intraperitoneally. Animals were allowed to drink 
5% glucose solution overnight to overcome drug-induced 
hypoglycemia. Hyperglycemia was confirmed 3 days after induction 
by assessing fasting blood glucose level. Animals with a fasting blood 
glucose level greater than 250 mg/dL were considered diabetic and 
included in the study.  
Animal groups for experimental studies  
Rats were acclimatized to the laboratory conditions at least for a 
week and they were divided into four groups of with four rats in 
each group as follows, 
Group I: Control rats administered 0.5 ml of saline for 42 days. 
Group II: STZ-induced diabetic control rats administered 0.5 ml of 
saline for 42 days. 
Group III :STZ–induced diabetic rats administered sugnil (100 
mg/kg body weight) for 42 days. 
Group IV: Control rats administered sugnil (100 mg/kg body 
weight) for 42 days. 
Analysis of mRNA expressions 
The STZ-induced diabetic rats were administered with sugnil for 42 
consecutive days. At the end of treatment schedule, two rats from 
four different experimental groups were sacrificed under mild 
anesthesia (non-fasted condition), the liver and kidney tissues were 
immediately removed, instantly soaked in liquid nitrogen and stored 
at -800
I - RNA Extraction from tissue samples 
C for study of mRNA using RT-PCR.  
Total mRNA was prepared separately from the tissues of individual 
rats in different experimental groups using TRIzol reagent.  
Homogenization 
About 15 mg of frozen liver tissue and 75 mg of frozen kidney tissue 
were homogenized separately in 1 ml of TRIzol reagent using a 
glass–Teflon homogenizer. 
Phase separation 
The homogenized tissue samples were incubated for 5 minutes at 
room temperature (300C) for complete dissociation of nucleoprotein 
complexes. After incubation, 0.2 ml of choloroform was added and 
the tubes were shaken vigorously by hand for 15 seconds. The entire 
content was then centrifuged at 12,000 x g for 15 minutes at 80
RNA precipitation 
C. 
Followed by centrifugation, the mixture was separated into a lower 
red, phenol–choloroform phase, an interphase and a colorless upper 
aqueous phase. RNA was present exclusively in an aqueous phase 
and was transferred to a fresh tube.  
RNA from the aqueous phase was precipitated by mixing with 0.5 ml 
isopropyl alcohol. The samples were incubated at room temperature 
for 10 minutes and then centrifuged at 12,000 x g for 10 mintues at 
80
RNA wash 
C. After centrifugation RNA precipitate was formed as gel like 
pellet on the side and bottom of the tube. 
The pellet was collected and 1 ml of 75% ethanol was added. The 
samples were vortexed and then centrifuged at 7,500 x g for 5 
minutes at 80
Redissolving the RNA  
C. 
At the end of the procedure, RNA pellet was air dried, and dissolved 
in RNase – free water. The concentration and purity of RNA 
preparation were checked by measuring the absorbance at 260 nm 
and 280 nm.  
The above mentioned RNA extraction procedure was performed 
individually to all the tissue samples dissected from rats in four 
different experimental groups. The extracted RNA’s were used as a 
template for the synthesis of first-strand of cDNA. 
II - First Strand cDNA Synthesis 
cDNA Synthesis was performed using superscript III first–strand 
synthesis system for RT-PCR (Invitrogen, USA) following 
manufacturer’s protocol as follows;  
As a first step, the following components were added into a thin-
walled 0.5 ml PCR tube to prepare cDNA synthesis mix. 1µg total 
RNA (extracted separately from tissues of rats in four different 
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experimental groups), 1 µl 50 mM oligo (dT)20, 1 µl 10 mM dNTP mix 
[10 µl dATP (100 mM), 10 µl dCTP (100 mM), 10 µl dGTP (100 mM), 
10 µl dTTP (100 mM)] and DEPC (diethyl pyrocarbonate) treated 
water to bring to volume of 10 µl. 
The above mix was incubated at 650C for 5 minutes and placed on 
ice for 1 minute. Then the following components were added in the 
order indicated below (as recommended by the manufacturer). The 
amount for each component is for 1 reaction only which can be 
scaled up according to need. 2 µl 10X RT buffer, 4 µl 25 mM Mgcl2, 2 
µl 0.1m DTT, 1 µl RNase OUT (40U/µl), 1 µl superscript III RT 
(200U/µl), and 10 µl of cDNA synthesis mix from above.  
The above mix was briefly centrifuged and incubated at 50C for 50 
minutes. The reaction was completed with incubation at 850C for 5 
minutes, followed by incubation in ice for 1 minute. The reaction mix 
was briefly centrifuged and 1 µl of RNaseH was added to the tube 
and incubated at 370C for 20 minutes. The synthesized cDNAs were 
stored at -20 0
SREBP-1 – Sterol Regulatory Element Binding Protein 1 
C for PCR amplification using gene specific primers. 
III - Primer Design 
For PCR amplification, the following genes were selected from 
previous work by scientists and from Gene bank database (http: 
//www. ncbi. nlm. nih. gov/).  
Fatty acid synthesis related genes – SREPB-1 and SREPB-2 
Fatty acid decomposition related gene – PPARα 
The house keeping gene _ β Actin 
The sequences of these genes were used to design primer for the RT 
PCR. The primers were ordered from GeNei, Bangalore. 1 µl of cDNA 
was used as a template for RT-PCR. The Primer sequences for the 
above mentioned genes are as follows;  
Forward primer: TCCCAGAGTAGCCCCTTGTCC (51→31
Reverse primer: CCAGTCCCCATCCACGAA (3
) 
1→51
SREBP-2 - Sterol Regulatory Element Binding Protein 2 
) 
Forward primer: ATCCGCCCACACTCACGCTCCTC (51→31
Reverse primer: GGCCGCATCCCTCGCACTG (3
) 
1→51
PPARα – Peroxisome Proliferator Activated Receptor-α 
) 
Forward primer: GACAAGGCCTCAGGATACCA (51→31
Reverse primer: GTCTTCTCAGCCATGCACAA (3
) 
1→51
β actin - House keeping gene 
) 
Forward primer: AGCCATGTACGTAGCCATCC(51→31
Reverse primer: CTCTCAGCTGTGGGTGGTGAA (3
) 
1→51
IV - Reverse Transcriptase PCR 
) 
The cDNAs synthesized from tissues of individual rats in four 
different experimental groups were amplified using the primers 
mentioned above. Polymerase chain reaction was performed in 40 µl 
reactions containing 84 pmol of each of two primers, 4 µl of 10 mM 
dNTP mix [10 µl dATP (100 mM), 10 µl dCTP (100 mM), 10 µl dGTP 
(100 mM), 10 µl dTTP (100 mM)], 4 µl of Mg free 10X buffer (100 
mM Tris pH 9.0 at 250C, 500 mM Kcl, 1% tritonX-100), 4 µl of 25 mM 
Mgcl2
 
 and 2 units of Taq DNA polymerase enzyme. The PCR reagents 
were assembled as a master mix that was split into reactions that 
received 1 µl of cDNA as template. PCR was performed with the 
reaction conditions mentioned in table.2. At the end, aliquots of the 
reactions were removed after a determined number of cycles and the 
reaction products were subjected to electrophoresis on agarose gel. 
Table 2: Thermal cycler conditions for selected genes 












SREPB-1 950 64C for 15s 0 72C for 40s 0  30 C for 30s 720 728bp C for 10m 
SREBP-2 940 65C for 1m 0 72C for 1m 0  30 C for 1m 720 416bp C for 10m 
PPARα 940 64C for 30s 0 72C for 30s 0  35 C for 1m 720 425bp C for 10m 
β ACTIN 940 60C for 30s 0 72C for 30s 0  35 C for 1m 720 357bp C for 10m 
 
V - Gel Electrophoresis and data acquisition 
The PCR amplified products of the selected genes were 
electrophorised using 1.0% agarose gel prepared in 1X Tris acetic 
acid EDTA buffer [0.5g of agarose dissolved by heating in 50 ml of 1X 
TAE buffer (40 mM Tris, 1 mM EDTA, pH 8.0)]. A dye solution 
consisting of bromophenol blue (0.25%), Xylene cyanol FF (0.25%) 
and 40% sucrose in water was added at 3 µl per DNA sample prior 
to electrophoresis. Electrophoresis was carried out in a horizontal 
electrophoresis unit. The agarose gel was formed using a gel caster 
and the dimensions of the gel were adjusted to 9.6 by 14.2 by 0.6 cm. 
The wells were made by using comb, the ladder DNA (10 µl) and 
samples (10 µl each) were loaded at wells using micropipette in the 
following manner. 
Lane 1 – DNA ladder sequence (1000 bp). 
Lane 2 – Amplicon of selected gene from control rats. 
Lane 3 – Amplicon of selected gene from diabetic control rats.  
Lane 4 – Amplicon of selected gene from control rats treated with 
sugnil (100 mg/kg).  
Lane 5 – Amplicon of selected gene from control rats treated with 
sugnil (100 mg/kg).  
The gel was allowed to run at 85 V, maximum Amp and maximum 
Watts for 1 hour 20 minutes or till the dye neared at the bottom of 
the gel using the high voltage power supply unit. The gel was then 
placed in the ethidium bromide staining solution (0.01 g/L) for 20 
minutes and transferred to destaining solution (1X TAE) for 30 
minutes. The resolved DNA in the gel was visualized under UV trans-
illuminator. Electrophoresis was carried out individually for all the 
selected genes to separate their PCR amplicons. At the end, the gels 
were photographed using a gel documentation system (Bio Rad, CA, 
USA) and the density of the PCR products was measured using a GS-
700 imaging densitometer. The housekeeping gene, β actin was 
amplified as a control gene (Fig. 1b, 2b & 3b). The level of mRNA was 
expressed as the ratio of signal intensity for each gene relative to 
that of β actin. All results were confirmed with at least three 
independent experiments.  
RESULTS  
Expression of mRNA in Liver 
In the liver, expressions of fatty acid decomposition related gene 
PPAR-α and fatty acid synthesis-related gene SREBP-2 were 
measured by real-time RT-PCR. The mRNA expression of PPAR-α 
was found to be decreased, where as the expression of SREBP-2 was 
significantly increased in streptozotocin induced diabetic rats when 
compared to normal control rats. Oral administration of sugnil for 42 
consecutive days effectively reversed the expression pattern of these 
genes to near normal as in the control rats. However, no significant 
difference was found in the expression pattern of these genes in 
control rats treated with sugnil (Fig.1a & 1c and 2a & 2c). 
Expression of mRNA in kidney  
In the kidney, the mRNA expression of SREBP-1 was significantly 
increased in streptozotocin induced diabetic rats when compared to 
normal control rats. Oral administration of sugnil for 42 consecutive 
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days significantly decreased the expression of this gene to near 
normal as in control rats. However, no significant difference was 
found in the renal expression of SREBP-1 in control rats treated with 
sugnil (Fig 3a&3c). 
 
 
Fig. 1(a): Expression of PPAR-α in liver 
 
 
































Fig: 1(c): Densitometry data analysis 
Fig. 1a, 1c: RT-PCR analysis of PPAR-α in liver. The band 
intensities of gene are normalized with that of a house keeping 
gene (β-actin) and the values are expressed as ratio of band 
intensity relative to β-actin. Values are mean ± SD of three 
independent experiments. Lane 1-Base pairs marker; Lane 2-
Control; lane 3-Diabetic control; lane 4-Diabetic+SUGNIL; lane 
5-Control+SUGNIL. *Significant as compared to Control. 
**
 
Significant as compared to Diabetic control (p<0.05, one way 
ANOVA followed by DMRT). 
 
Fig. 2a: Expression of SREBP-2 in liver 
 




























Fig. 2c: Densitometry data analysis 
Fig. 2a, 2c: RT-PCR analysis of SREBP-2 in liver. The band 
intensities of gene are normalized with that of a house keeping 
gene (β-actin) and the values are expressed as ratio of band 
intensity relative to β-actin. Values are mean ± SD of three 
independent experiments. Lane 1-Base pairs marker; Lane 2-
Control; lane 3-Diabetic control; lane 4-Diabetic+SUGNIL; lane 
5-Control+SUGNIL. *Significant as compared to Control. 
**
 
Significant as compared to Diabetic control (p<0.05, one way 
ANOVA followed by DMRT). 
 
Fig. 3a: Expression of SREBP-1 in kidney 
 
 
Fig. 3b: β-ACTIN 
 
DISCUSSION  
To investigate the lipid lowering effects of sugnil changes in the 
expression of transcriptional factors involved in hepatic lipogenesis 
were examined using RT-PCR assay. Peroxisome proliferator-
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activated receptor (PPAR), a ligand activated transcription factor, is 
highly expressed in liver, heart, and skeletal muscle [20]. PPAR-α 
mediated responses have been traditionally studied in the liver. 
PPAR-α activation mediates expression of genes regulating lipid 
oxidation [21]. Both, natural and synthetic ligands are found to 
activate PPAR-α and thereby regulate the lipid metabolism in man 
and animals [6,14]. In recent years, many plant extracts and 
traditional plant formulations have been shown to possess PPAR-α 
































Fig. 3c: Densitometry data analysis 
Fig. 3a, 3c: RT-PCR analysis of SREBP-1 in kidney. The band 
intensities of gene are normalized with that of a house keeping 
gene (β-actin) and the values are expressed as ratio of band 
intensity relative to β-actin. Values are mean ± SD of three 
independent experiments. Lane 1-Base pairs marker; Lane 2-
Control; lane 3-Diabetic control; lane 4-Diabetic+SUGNIL; lane 
5-Control+SUGNIL. *Significant as compared to Control. 
**
 
Significant as compared to Diabetic control (p<0.05, one way 
ANOVA followed by DMRT). 
In this context, sugnil, a traditional antidiabetic polyherbal 
formulation was examined for its PPAR-α modulatory effect in 
streptozotocin induced diabetic rats. Results of this study showed 
that the expression of PPAR-α was decreased in streptozotocin 
induced diabetic rats. This effect may be due to the hyperglycemic 
condition caused by streptozotocin and/or loss of insulin signaling. 
However, oral administration of sugnil for 42 consecutive days 
effectively increased the expression of PPAR- α in the liver of STZ-
induced diabetic rats. This possible effect of sugnil may be due to the 
presence of bioactive compound(s), which could act as a ligand for 
PPAR-α activation. The activated transcription factor PPAR-α 
induces the mRNA expressions of target genes responsible for fatty 
acid β oxidation. This was evidenced by normal levels of 
triglycerides and high density lipoproteins observed in sugnil 
treated diabetic rats [2]. Further, it has been reported that PPAR-α 
activation lowers the cholesterol concentration in rat liver, plasma 
and lipoproteins by reducing the amount of nuclear SREBP-2 
thereby decreasing cholesterol synthesis and uptake [22]. 
Consistent with this finding, the present study results also showed 
that the activated PPAR-α decreased the expression of SREBP-2 in 
the liver of sugnil treated diabetic rats. This might be a reason 
behind the decreased concentrations of total cholesterol observed in 
the liver and plasma of sugnil treated diabetic rats [2]. 
. Over all, these results strongly suggest that sugnil behave like 
natural ligand for PPAR-α activation. This leads in turn to the 
diminished expression of SREBP-2. Hence, the molecular mechanism 
of sugnil action in the regulation of circulatory and hepatic lipid 
metabolism in diabetic rats might be modulation of PPAR-α and 
SREBP-2 gene expression.  
SREBP-1 plays an important role in the regulation of lipid 
homeostasis in kidney; an altered regulation of this transcription 
factor may be involved in diabetic nephropathy by modulating renal 
lipid metabolism. A previous study has shown that the expression of 
SREBP-1 was increased in the kidney cortex of STZ-induced diabetic 
rats, resulting in up-regulation of enzymes responsible for fatty acid 
synthesis and, as a consequence, high renal triglyceride content, and 
was associated with mesangial expansion and glomerulosclerosis. 
Treatment of diabetic rats with insulin to correct the hyperglycemia 
prevented the increase in renal expression of SREBP-1 and the renal 
accumulation of triglyceride [23]. The result of the present study 
showed that the expression of SREBP-1 was found to be increased in 
the kidney cortex of STZ-induced diabetic rats. Hyperglycemic 
condition caused by streptozotocin might be responsible for this 
effect. However, oral administration of sugnil for 42 consecutive 
days effectively decreased the expression of SREBP-1 in the kidney 
of STZ-induced diabetic rats. This possible effect of sugnil might be 
due to the stimulation of insulin secretion from pancreatic β cells, 
since insulin was reported to normalize SREBP-1 expression in STZ-
induced diabetic rats [23]. Insulin stimulatory effect was directly 
witnessed by increased concentration of serum insulin reported in 
sugnil treated diabetic rats [24]. Therefore, the results suggest that 
down-regulation of renal SREBP-1 through insulin stimulation might 
be the mechanism of sugnil action in lowering renal lipid contents. 
CONCLUSION 
The regulation of lipid metabolism by sugnil might involve up-
regulation of PPARα and diminished expression of SREBP-2 in liver 
and SREBP-1 in kidney of diabetic rats. The bioactive compound(s) 
present in sugnil might act as a natural ligand and normalized the 
expression of these transcription factors. These possible effects of 
sugnil may arrest the development and progression of 
atherosclerosis and related cardiovascular complications in diabetes 
mellitus. Hence, its therapeutic usage can improve the quality of life 
in diabetic patients. 
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